Genesis Therapeutics is a biotechnology company leveraging artificial intelligence and machine learning to revolutionize the drug discovery process. Established in 2019, the company has developed GEMS (Genesis Exploration of Molecular Space), an advanced molecular AI platform that enhances the identification and optimization of small molecules, particularly for difficult-to-target diseases. Genesis operates with a mission to provide breakthrough therapies for patients facing severe conditions, emphasizing interdisciplinary collaboration among researchers, engineers, and drug developers. The company has forged partnerships with major pharmaceutical firms, including Eli Lilly and Genentech, and continues to grow its pipeline with programs targeting high-value and previously undruggable targets. Headquartered in Burlingame, California, with a laboratory in San Diego, Genesis Therapeutics promotes an inclusive work culture and values innovative approaches to solving complex health challenges.